A new rating scale for Alzheimer's disease.

By W. Rosen, R. Mohs, K. Davis. 1984

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Jiayu Zhou
2. Jieping Ye
3. Jun Liu
4. Dinggang Shen
5. Daoqiang Zhang
6. Lei Yuan
7. Yu Zhang
8. Susan M. Landau

Citations in the corpus

• Visual Feature Attribution Using Wasserstein GANs (2017, methodology): “The subjects are ordered by increasing progression of the disease as measured by the ADAS13 cognition exam [47].”
• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. (2007, methodology): “Cognitive performance was measured by the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAScog ; Rosen et al., 1984) in the studies in mild-to-moderate AD as well as in the vascular dementia studies.”
• Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease (2014, background): “The carrier study was conducted at 170 sites in the United States from December 2007 through April 2012, and the noncarrier study was conducted at 218 sites in the United States (195 sites), Canada (17), Germany (4), and Austria (2) from December 2007 through June 2012.”
• Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia (2003, methodology): “The secondary outcome variable was the Alzheimer’s Disease Assessment Scale – Cognition (ADAS–Cog; Rosen et al, 1984); this is a more sensitive scale measuring cognitive function and including more items that assess short-term memory.”
• Fear recognition deficits after focal brain damage (2000, unknown): “That certain emotional expressions are more difficult to recognize is clearly illustrated by the results of cross-cultural studies of facial emotion processing.8-10 These large-scale studies have shown that happiness From the Neurology Section (Dr. Rapcsak) and the Psychology Service (Dr. Comer), VA”
• Modeling disease progression via multi-task learning (2013, unknown): “ADAS-Cog is the gold standard in AD drug trial for cognitive function assessment (Rosen et al., 1984).”
• Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014, methodology): “The Alzheimer’s Disease Assessment Scale (ADAS) was specifically developed to measure the severity of symptoms commonly seen in AD (Rosen et al., 1984).”
• A multi-task learning formulation for predicting disease progression (2011, methodology): “ADAS-Cog is the gold standard in AD drug trial for cognitive function assessment [31].”
• Multi-Modal Multi-Task Learning for Joint Prediction of Multiple Regression and Classification Variables in Alzheimer’s Disease (2011, methodology): “, 1975), while ADAS-Cog is a global measure encompassing the core symptoms of AD (Rosen et al., 1984).”
• Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline (2008, methodology): “The ADAS-cog is a validated psychometric assessment scale for the domains of attention, memory, orientation, language ability, and praxis in Alzheimer disease (4).”